Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network-Reference-Cited by-同舟云学术

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network

Published:2010-09 Issue:9 Volume:21 Page:1834-1838
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Malouf G.G.,Camparo P.,Oudard S.,Schleiermacher G.,Theodore C.,Rustine A.,Dutcher J.,Billemont B.,Rixe O.,Bompas E.,Guillot A.,Boccon-Gibod L.,Couturier J.,Molinié V.,Escudier B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/9/1834/339335/mdq029.pdf

Reference18 articles.

1. Renal carcinomas associated with Xp11.2 translocations/TFE3 gene fusions;Argani,2004

2. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry;Komai;Clin Cancer Res,2009

3. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature;Camparo;Am J Surg Pathol,2008

4. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy;Rais-Bahrami;Urology,2007

5. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum;Argani;Am J Surg Pathol,2007

Cited by 196 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Clinicopathological Characteristics and Prognosis of 55 Patients With TFE3-Rearranged Renal Cell Carcinomas;Clinical Genitourinary Cancer;2024-10

2. NMRK2 is an efficient diagnostic indicator for Xp11.2 translocation renal cell carcinoma;The Journal of Pathology;2024-08-02

3. A genetic basis for sex differences in Xp11 translocation renal cell carcinoma;Cell;2024-08

4. Pregnant patient with Xp11.2/transcription factor E3 translocation renal cell carcinoma: a case report and literature review;Frontiers in Oncology;2024-06-26

5. Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study;Journal of Urologic Oncology;2024-03-31